IMR Press / FBS / Volume 13 / Issue 2 / DOI: 10.52586/S562
Open Access Review
Anti PD-L1 antibody: is there a histologic-oriented efficacy? Focus on atezolizumab in squamous cell non-small cell lung cancer
Show Less
1 Oncology Unit, IRCCS MultiMedica, Sesto San Giovanni, 20099 Milan, Italy
2 Oncology Unit, ASST-Monza, San Gerardo Hospital, Monza, 20900 Monza-Brianza, Italy
*Correspondence: (Maria Gemelli)
Front. Biosci. (Schol Ed) 2021, 13(2), 190–201;
Submitted: 3 April 2021 | Revised: 15 May 2021 | Accepted: 17 May 2021 | Published: 3 December 2021
Copyright: © 2021 The Author(s). Published by BRI.
This is an open access article under the CC BY 4.0 license (

Squamous cell lung cancer (SqCLC) is the second most common histotype of non-small cell lung cancer (NSCLC) and is characterized by severe prognosis and lack of specific target agents. Atezolizumab is the first anti Programmed Death Ligand-1 (PDL-1) inhibitor approved for NSCLC patients of both histology in case of disease progression after first or further lines of therapy. Numerous studies are investigating the potential role of atezolizumab in different therapeutic setting, including SqCLC subtype. We searched for published clinical trials in Pubmed database, using the terms “atezolizumab”, “squamous cell lung cancer”, “NSCLC” and “non-small cell lung cancer”. We also searched for recently concluded and not yet published or ongoing trials in and in data from the latest international congresses. The aim of this review is to summarize current evidence on atezolizumab in SqCLC, from first line setting to novel potential indications from ongoing trials. Strengths and weaknesses of atezolizumab treatment were highlighted to speculate the role of this immune checkpoint inhibitor in novel future clinical scenarios.

Immune check point inhibitors
Squamous non-small cell lung cancer
First-line therapy
Advanced setting
Neo-adjuvant setting
Back to top